Shiqing Chen

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

Wenwen Zhang, Shuang Tong, Bingyang Hu et al. · Journal for ImmunoTherapy of Cancer · 2023 · 126 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

Wu‐tong Ju, Ronghui Xia, Dongwang Zhu et al. · Nature Communications · 2022 · 121 citations · Full text

Medicine, Oncology, Pharmacology +17

24-hour-restraint stress induces long-term depressive-like phenotypes in mice

Xixia Chu, Zhiqiang Hu, Jingyu Lou et al. · Scientific Reports · 2016 · 97 citations · Full text

Medicine, Neuroscience, Psychiatry +17

Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes

Xiaofeng Chen, Deqiang Wang, Jing Liu et al. · Journal for ImmunoTherapy of Cancer · 2021 · 65 citations · Full text

Medicine, Immunology, Oncology +17

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Zhengbo Song, Yuping Li, Shiqing Chen et al. · BMC Medicine · 2022 · 65 citations · Full text

Medicine, Oncology, Pharmacology +17